Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells
Cho-Hao Lin, Jimmy Chun‐Tien Kuo, Li Ding, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 13

Showing 13 citing articles:

Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives
Moustafa Ghanem, Irene Caffa, Fiammetta Monacelli, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2092-2092
Open Access | Times Cited: 9
Super enhancer lncRNAs: a novel hallmark in cancer
Ping Song, Rongyan Han, Fan Yang
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
MYC in liver cancer: mechanisms and targeted therapy opportunities
Furong Liu, Zhibin Liao, Zhanguo Zhang
Oncogene (2023) Vol. 42, Iss. 45, pp. 3303-3318
Closed Access | Times Cited: 16
Oncogene-induced matrix reorganization controls CD8+ T cell function in the soft-tissue sarcoma microenvironment
Ashley M. Fuller, Hawley C. Pruitt, Ying Liu, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 11
Open Access | Times Cited: 5
Super-enhancers in hepatocellular carcinoma: regulatory mechanism and therapeutic targets
Xuejin Lu, Meizi Zhu, Xueliang Pei, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Targeting Dysregulated Epigenetic Modifiers With Kidney‐Targeted Nanotherapeutics for Polycystic Kidney Disease
Joshua Giblin, Rüdiger Simon, Jose Zarate‐Diaz, et al.
Journal of Biomedical Materials Research Part A (2025) Vol. 113, Iss. 4
Closed Access
BRD4: an effective target for organ fibrosis
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential
Ling Tang, Peng Lin, Chao Tan, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma
Chunjia Yin, Shuting Jia, Xiaojuan Yang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116444-116444
Closed Access | Times Cited: 1
Targeting BRD4 mitigates hepatocellular lipotoxicity by suppressing the NLRP3 inflammasome activation and GSDMD-mediated hepatocyte pyroptosis
Fangyuan Chen, Shuyu Li, Min Liu, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 1
An interplay between BRD4 and G9a regulates skeletal myogenesis
Naidi Yang, Dipanwita Das, Shilpa Rani Shankar, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 3
Will AMPK be a potential therapeutic target for hepatocellular carcinoma?
Guo Chen, Mingyuan Li, Jingyi Yang, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 7, pp. 3241-3258
Open Access
Screening and molecular docking verification of feature genes related to phospholipid metabolism in hepatocarcinoma caused by hepatitis B
Jian Zhang, Fengmei Zhang, Lei Zhang, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access
Page 1

Scroll to top